| human | Q5 |
| P2080 | AcademiaNet ID | 1033602 |
| P2671 | Google Knowledge Graph ID | /g/11c3yry61n |
| P3762 | openMLOL author ID | 308040 |
| P27 | country of citizenship | Germany | Q183 |
| P69 | educated at | University of Bonn | Q152171 |
| P108 | employer | University of Cologne | Q54096 |
| P734 | family name | Schmutzler | Q28870331 |
| Schmutzler | Q28870331 | ||
| Schmutzler | Q28870331 | ||
| P735 | given name | Rita | Q1094218 |
| Rita | Q1094218 | ||
| P1412 | languages spoken, written or signed | German | Q188 |
| P106 | occupation | researcher | Q1650915 |
| gynaecologist | Q2640827 | ||
| P21 | sex or gender | female | Q6581072 |
| Q36016386 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer |
| Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
| Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
| Q64386490 | A 24-color metaphase-based radiation assay discriminates heterozygous BRCA2 mutation carriers from controls by chromosomal radiosensitivity |
| Q51569689 | A BRCA1 promoter variant (rs11655505) and breast cancer risk. |
| Q59355837 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk |
| Q37313778 | A breast cancer risk haplotype in the caspase-8 gene |
| Q36511037 | A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity |
| Q84920409 | A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk |
| Q29417036 | A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age. |
| Q35089479 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population |
| Q36435849 | A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. |
| Q92711687 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis |
| Q40484664 | A network of clinically and functionally relevant genes is involved in the reversion of the tumorigenic phenotype of MDA-MB-231 breast cancer cells after transfer of human chromosome 8. |
| Q36152991 | A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers |
| Q57305942 | A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer |
| Q53315710 | A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women. |
| Q52605797 | A variant affecting miRNAs binding in the circadian gene Neuronal PAS domain protein 2 (NPAS2) is not associated with breast cancer risk. |
| Q37417780 | AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study |
| Q34635681 | Activating somatic FGFR2 mutations in breast cancer |
| Q39437211 | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers |
| Q36882665 | An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers |
| Q36073563 | An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression |
| Q33901361 | An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers |
| Q35618307 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers |
| Q31109088 | Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction |
| Q35242849 | Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers |
| Q39053021 | Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer |
| Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
| Q94355861 | Association of () polymorphisms with breast cancer risk |
| Q37292963 | Association of ESR1 gene tagging SNPs with breast cancer risk |
| Q46402532 | Association of NCOA3 polymorphisms with breast cancer risk |
| Q36072765 | Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study |
| Q46707380 | Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis |
| Q61853741 | Association of allelic losses on human chromosomal arms 11q and 16q in sporadic breast cancer |
| Q36178189 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. |
| Q54657396 | Association of death receptor 4 haplotype 626C-683C with an increased breast cancer risk. |
| Q45341994 | Association of death receptor 4 variant (683A > C) with ovarian cancer risk in BRCA1 mutation carriers |
| Q37268494 | Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry |
| Q51836207 | Association of genetic variants in the Rho guanine nucleotide exchange factor AKAP13 with familial breast cancer. |
| Q114182713 | Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment |
| Q44748122 | Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer |
| Q54620954 | Association of prolactin and its receptor gene regions with familial breast cancer. |
| Q53651814 | Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant. |
| Q34801008 | Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q35957703 | Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer |
| Q35523236 | Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers |
| Q28240593 | Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer |
| Q57056093 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis |
| Q37261138 | BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk |
| Q37220433 | BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance |
| Q33284720 | BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study |
| Q47549253 | BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer |
| Q37602423 | Basic and clinical aspects of GnRH-agonists in reproduction |
| Q56771447 | Benefits and risks of breast cancer screening |
| Q52069084 | Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. |
| Q37627536 | Breast cancer in young women after treatment for Hodgkin's disease during childhood or adolescence--an observational study with up to 33-year follow-up |
| Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
| Q36998293 | COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration |
| Q92005489 | Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families |
| Q34963894 | Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q56928420 | Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons FromBRCA1/2-Associated Breast Cancer |
| Q73010284 | Characterization of the human Rad51 genomic locus and examination of tumors with 15q14-15 loss of heterozygosity (LOH) |
| Q44470570 | Chromosomal region 15q21.1 is a frequent target of allelic imbalance in advanced breast carcinomas |
| Q36839777 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q34394665 | Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction |
| Q35889575 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. |
| Q24655824 | Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q33742096 | Common genetic variants and modification of penetrance of BRCA2-associated breast cancer |
| Q33947829 | Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q36393232 | Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers |
| Q35870067 | Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q37434133 | Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q34213403 | Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers |
| Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q31108170 | Comparison of gene expression data from human and mouse breast cancers: identification of a conserved breast tumor gene set. |
| Q34181322 | Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer |
| Q34002454 | Copy number variant in the candidate tumor suppressor gene MTUS1 and familial breast cancer risk |
| Q57266620 | Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer |
| Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q38851169 | Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation |
| Q28388475 | Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations |
| Q21144874 | DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q57191514 | DNA methylation array analyses identified breast cancer-associatedHYAL2methylation in peripheral blood |
| Q37665624 | DNA methylation array analysis identifies breast cancer associated RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA. |
| Q43450774 | Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker |
| Q37138925 | Effects of lifestyle intervention in BRCA1/2 mutation carriers on nutrition, BMI, and physical fitness (LIBRE study): study protocol for a randomized controlled trial |
| Q37193459 | Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy |
| Q48212974 | Epigenetic silencing of the candidate tumor suppressor gene PROX1 in sporadic breast cancer |
| Q33614244 | Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers |
| Q35009015 | Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases |
| Q37481884 | Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). |
| Q37745041 | Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers |
| Q35653910 | Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk |
| Q34613604 | Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers |
| Q49061461 | Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer. |
| Q37342144 | Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation |
| Q36618879 | Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas |
| Q38332544 | Expression of the ATM gene is significantly reduced in sporadic breast carcinomas |
| Q47576949 | Expression of the tumor suppressor gene PTEN is not altered in the progression of ovarian carcinomas and does not correlate with p27Kip1 expression. |
| Q35999309 | FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor |
| Q43994970 | Familial ovarian dysgerminomas (Swyer syndrome) in females associated with 46 XY-karyotype |
| Q37236216 | Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). |
| Q36111237 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus |
| Q36087170 | Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
| Q92480972 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes |
| Q39844032 | Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer |
| Q36248936 | Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk |
| Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
| Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
| Q34979715 | Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium |
| Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
| Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
| Q51764547 | Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. |
| Q37739048 | Genetic modifiers of CHEK2*1100delC-associated breast cancer risk |
| Q35925620 | Genetic predisposition to ductal carcinoma in situ of the breast |
| Q35151684 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast |
| Q35536253 | Genetic research in embryology |
| Q53291654 | Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. |
| Q35022825 | Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
| Q36422109 | Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium |
| Q44752870 | Genetic variation in the major mitotic checkpoint genes does not affect familial breast cancer risk |
| Q30000080 | Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent |
| Q28388497 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types |
| Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
| Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
| Q63681757 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q27008356 | Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk |
| Q64040390 | Genome-wide association study of germline variants and breast cancer-specific mortality |
| Q61853730 | Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinoma |
| Q38373098 | Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial |
| Q39370774 | Germline Mutations in Triple-Negative Breast Cancer |
| Q28280022 | Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene |
| Q45898145 | Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer. |
| Q35382206 | Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers |
| Q57471595 | Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study |
| Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
| Q35019634 | Hereditary breast and ovarian cancer: new genes, new treatments, new concepts |
| Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
| Q36720814 | Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk |
| Q44028747 | Identification of a DMBT1 polymorphism associated with increased breast cancer risk and decreased promoter activity |
| Q39900757 | Identification of brain- and bone-specific breast cancer metastasis genes |
| Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
| Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
| Q35541663 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer |
| Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
| Q35050959 | Impact of Prophylactic Mastectomy in BRCA1/2 Mutation Carriers |
| Q38610326 | Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility |
| Q43506703 | Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer |
| Q58592781 | Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors o |
| Q58124814 | Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Brea |
| Q34081324 | Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer |
| Q92313654 | Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification |
| Q57191573 | Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair |
| Q28267893 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair |
| Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
| Q47738885 | Limited relevance of the CHEK2 gene in hereditary breast cancer |
| Q61853709 | Loss of heterozygosity (LOH) atp53 is correlated with LOH atBRCA1 andBRCA2 in various human malignant tumors |
| Q43255116 | Low-risk variants FGFR2, TNRC9 and LSP1 in German familial breast cancer patients |
| Q51705297 | MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases. |
| Q114182490 | Mendelian randomisation study of smoking exposure in relation to breast cancer risk |
| Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
| Q34123806 | Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q35399681 | New avenues in secondary and tertiary prevention of breast cancer |
| Q37356243 | Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. |
| Q37237352 | No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q37079859 | No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing |
| Q55389200 | Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature. |
| Q33583309 | Nuclear receptor coregulator SNP discovery and impact on breast cancer risk |
| Q56240758 | Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation |
| Q30080035 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial |
| Q29619615 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial |
| Q36280191 | Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers |
| Q47143943 | PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. |
| Q45113834 | PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas |
| Q112572520 | Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes |
| Q35737888 | Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) |
| Q50033737 | Patient-Centered Care in Breast Cancer Genetic Clinics. |
| Q45386947 | Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q48296505 | Polymorphisms in BRCA2 resulting in aberrant codon-usage and their analysis on familial breast cancer risk |
| Q36066735 | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression |
| Q43613530 | Polymorphisms in genes involved in GH1 release and their association with breast cancer risk |
| Q80636308 | Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer |
| Q36356727 | Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q39958494 | Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer |
| Q46567658 | Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). |
| Q52808311 | Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. |
| Q49340500 | Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. |
| Q54944326 | Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. |
| Q36512097 | RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies |
| Q36009422 | RAD51B in Familial Breast Cancer |
| Q37690250 | RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families |
| Q24643967 | Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy |
| Q46585200 | Re: Association of a common variant of the CASP8 gene with reduced risk of breast cancer |
| Q37113159 | Real-time MR-guided wire localization of breast lesions by using an open 1.0-T imager: initial experience |
| Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
| Q56624494 | Risikofaktoren und Prävention des Mammakarzinoms |
| Q37300024 | Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. |
| Q36295137 | Risk-reducing Surgery in Women at Risk for Familial Breast or Ovarian Cancer |
| Q38717239 | Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers |
| Q80442969 | SNPs in ultraconserved elements and familial breast cancer risk |
| Q50787069 | Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study. |
| Q42678425 | Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas. |
| Q24813671 | Strong evidence that the common variant S384F in BRCA2 has no pathogenic relevance in hereditary breast cancer |
| Q44148124 | Supplemental screening ultrasound increases cancer detection yield in BRCA1 and BRCA2 mutation carriers |
| Q28297342 | Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer |
| Q24810703 | TP53-binding protein variants and breast cancer risk: a case-control study |
| Q33927384 | Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study |
| Q49817640 | The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. |
| Q33300099 | The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study |
| Q38944944 | The CpG island methylator phenotype in breast cancer is associated with the lobular subtype |
| Q34096106 | The Epidemiology and Aetiology of Female Breast Cancer |
| Q91178389 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer |
| Q64116004 | The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With or Mutations |
| Q34115636 | The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q37578078 | The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers |
| Q48516083 | The RAD51C exonic splice-site mutations c.404G>C and c.404G>T are associated with familial breast and ovarian cancer. |
| Q37401496 | The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q40234422 | The association between breast cancer and S100P methylation in peripheral blood by multicenter case-control studies |
| Q38309964 | The functional genetic variant Ile646Val located in the kinase binding domain of the A-kinase anchoring protein 10 is associated with familial breast cancer |
| Q45154642 | The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk |
| Q33739428 | The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study |
| Q53639998 | The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer. |
| Q33263818 | Transcription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study |
| Q89961489 | Transcriptome-wide association study of breast cancer risk by estrogen-receptor status |
| Q92994868 | Two truncating variants in FANCC and breast cancer risk |
| Q34096302 | Vacuum-Sealing as a Treatment Option for Severe Anthracycline Extravasation in a Breast Cancer Patient |
| Q53769372 | [Counselling, genetic testing and prevention in women with hereditary breast- and ovarian cancer. Interdisciplinary recommendations of the consortium "Hereditary Breast- and Ovarian Cancer" of the German Cancer AiD]. |
| Q54183381 | [Molekulargenetische Diagnostik - Was wissen die Maschinen? Was wollen wir wissen?] |
| Q51239985 | [Risk-adapted surveillance: focus on familial breast and ovarian cancer]. |
| Q46521646 | c-MYC Asn11Ser is associated with increased risk for familial breast cancer |
| Rita Schmutzler | wikipedia |
Search more.